Manufacturer of Controlled Substances; Notice of Registration, 46234-46235 [E9-21527]
Download as PDF
<![CDATA[
46234
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
of controlled substances listed in
schedules I and II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19599), Norac
Inc., 405 S. Motor Avenue, P.O. Box
577, Azusa, California 91702–3232,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Methamphetamine (1105), a basic class
of controlled substance listed in
schedule II.
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 USC 823(a) and determined
that the registration of Norac, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Norac, Inc. to ensure that
the company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 USC 823, and
in accordance with 21 CFR 1301.33, the
above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Schedule
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
I
II
II
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls which are
DEA exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siemens Healthcare Diagnostics Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Siemens Healthcare
Diagnostics Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21531 Filed 9–4–09; 8:45 am]
Drug
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers for further
manufacture or to manufacture
pharmaceutical dosage forms.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Penick Corporation to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Penick Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21529 Filed 9–4–09; 8:45 am]
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21532 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19597), Penick
Corporation, 33 Industrial Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
jlentini on DSKJ8SOYB1PROD with NOTICES
Schedule
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19598), Siemens
Healthcare Diagnostics Inc., Attn: RA,
100 GBC Drive, Mail Stop 514, Newark,
Delaware 19702, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
VerDate Nov<24>2008
17:32 Sep 04, 2009
Jkt 217001
Drug
Schedule
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
PO 00000
Frm 00155
Fmt 4703
Sfmt 4703
II
II
II
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19598), AMRI
Rensselaer, Inc., 33 Riverside Avenue,
Rensselaer, New York 12144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
E:\FR\FM\08SEN1.SGM
08SEN1
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Dextropropoxyphene, bulk (nondosage form) (9273).
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
AMRI Rensselaer, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated AMRI Renssealaer Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21527 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
jlentini on DSKJ8SOYB1PROD with NOTICES
United States Parole Commission
Record of Vote of Meeting Closure
(Pub. L. 94–409) (5 U.S.C. 552b)
I, Isaac Fulwood, of the United States
Parole Commission, was present at a
meeting of said Commission, which
started at approximately 2 p.m., on
VerDate Nov<24>2008
17:32 Sep 04, 2009
Jkt 217001
Thursday, August 20, 2009, at the U.S.
Parole Commission, 5550 Friendship
Boulevard, 4th Floor, Chevy Chase,
Maryland 20815. The purpose of the
meeting was to decide one petition for
reconsideration pursuant to 28 CFR
Section 2.27. Four Commissioners were
present, constituting a quorum when the
vote to close the meeting was submitted.
Public announcement further
describing the subject matter of the
meeting and certifications of General
Counsel that this meeting may be closed
by vote of the Commissioners present
were submitted to the Commissioners
prior to the conduct of any other
business. Upon motion duly made,
seconded, and carried, the following
Commissioners voted that the meeting
be closed: Isaac Fulwood, Cranston J.
Mitchell, Edward F. Reilly, Jr. and
Patricia K. Cushwa.
In witness whereof, I make this official
record of the vote taken to close this
meeting and authorize this record to be
made available to the public.
Dated: August 27, 2009.
Isaac Fulwood,
Chairman, U.S. Parole Commission.
[FR Doc. E9–21498 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–01–M
DEPARTMENT OF LABOR
Office of the Secretary
Submission for OMB Review:
Comment Request
September 1, 2009.
The Department of Labor (DOL)
hereby announces the submission of the
following public information collection
requests (ICR) to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995
(Pub. L. 104–13, 44 U.S.C. chapter 35).
A copy of each ICR, with applicable
supporting documentation; including
among other things a description of the
likely respondents, proposed frequency
of response, and estimated total burden
may be obtained from the RegInfo.gov
Web site at https://www.reginfo.gov/
public/do/PRAMain or by contacting
Mary Beth Smith-Toomey on 202–693–
4223 (this is not a toll-free number)/
e-mail: DOL_PRA_PUBLIC@dol.gov.
Interested parties are encouraged to
send comments to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for the
Department of Labor—VETS, Office of
Management and Budget, Room 10235,
Washington, DC 20503, Telephone:
202–395–7316/Fax: 202–395–5806
PO 00000
Frm 00156
Fmt 4703
Sfmt 4703
46235
(these are not toll-free numbers), E-mail:
OIRA_submission@omb.eop.gov within
30 days from the date of this publication
in the Federal Register. In order to
ensure the appropriate consideration,
comments should reference the OMB
Control Number (see below).
The OMB is particularly interested in
comments which:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Agency: Office of the Assistance
Secretary for Administration and
Management.
Type of Review: Extension without
change of an existing OMB Control
Number.
Title of Collection: Customer
Satisfaction Surveys and Conference
Evaluations Generic Clearance.
OMB Control Number: 1225–0059.
Affected Public: Individuals.
Total Estimated Number of
Respondents: 200,000.
Total Estimated Annual Burden
Hours: 20,000.
Total Estimated Annual Costs Burden
(does not include hourly wage costs): $0.
Description: The Department is
requesting OMB approval for the
continued use of a generic clearance
process for customer satisfaction and
conference evaluation surveys.
Customer satisfaction and conference
evaluation surveys provide important
information on customer attitudes about
the delivery and quality of agency
products and services and will be used
as part of an ongoing process to improve
DOL products and products. For
additional information, see related
notice published at Volume 74 FR
26426 on June 2, 2009.
Agency: Office of the Assistance
Secretary for Administration and
Management.
Type of Review: Extension without
change of an existing OMB Control
Number.
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Pages 46234-46235]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21527]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated April 17, 2009, and published in the Federal
Register on April 29, 2009, (74 FR 19598), AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New York 12144, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the basic classes of controlled substances
listed in schedules I and II:
[[Page 46235]]
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Dextropropoxyphene, bulk (non-dosage form) II
(9273).
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance will be further synthesized to bulk manufacture a
synthetic THC (7370). No other activity for this drug code is
authorized for this registration.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
AMRI Rensselaer, Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated AMRI Renssealaer Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-21527 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
